Le Lézard
Classified in: Health
Subjects: SVY, POL, PSF, STP

Representative Bahr Lauds the Accomplishments of NPLEx in the First Quarter of 2015



JEFFERSON CITY, Mo., June 29, 2015 /PRNewswire/ -- Missouri State Representative Kurt Bahr (R-O'Fallon) today released the 2015 first quarter data from the state's real-time, stop-sale system, known as the National Precursor Log Exchange (NPLEx).

States across the United States are using NPLEx, making Missouri one of 31 across the country that currently utilize the system to automatically block unlawful, attempted pseudoephedrine (PSE) purchases at the point of sale.  NPLEx aids retailers and law enforcement officers as they work together to seek to stop criminals from purchasing medicine containing PSE and attempt to divert the decongestant to meth. NPLEx has played a vital role across the country limiting the illegal sale of PSE and stopping domestic meth production.

During the first quarter of 2015, the NPLEx system in Missouri helped block the sale of 4,390 boxes of PSE, keeping 11,401 grams from being used illegally.

"In the first quarter of 2015, NPLEx again proved that it is an important tool for law officers in their fight against meth," said Representative Bahr. "Our state has seen a decline in domestic meth production in recent years as meth criminals find it harder to make the drug. This does not mean the fight is over. Missouri must fight the increasing amount of meth coming in from Mexico as drug cartels replace what previously had been domestically produced. I have no doubt that our state will stand up to this drug and continue to make sure our addicts our treated, while maintaining law-abiding citizens' access to cold and allergy medications containing PSE."

SOURCE Missouri State Representative Kurt Bahr


These press releases may also interest you

at 18:34
Blessed Herbs Cafe and Mount Zion Rastafarian Church founder and practicing Rasta George Metropoulos today announced the launch of the organization's first holiday season food and cash drive. Directly benefiting the neighborhood's less fortunate...

at 11:40
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...

at 10:47
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriahtm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)...

at 10:30
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight...

at 08:48
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality...

at 08:32
The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...




News published on 29 june 2015 at 12:30 and distributed by: